U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting